These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 30628771)
1. Lipolysis-Permeation Setup for Simultaneous Study of Digestion and Absorption in Vitro. Keemink J; Mårtensson E; Bergström CAS Mol Pharm; 2019 Mar; 16(3):921-930. PubMed ID: 30628771 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Cellular Monolayers and an Artificial Membrane as Absorptive Membranes in the in vitro Lipolysis-permeation Assay. Keemink J; Hedge OJ; Bianco V; Hubert M; Bergström CAS J Pharm Sci; 2022 Jan; 111(1):175-184. PubMed ID: 34516987 [TBL] [Abstract][Full Text] [Related]
3. Suitability of Artificial Membranes in Lipolysis-Permeation Assays of Oral Lipid-Based Formulations. Hedge OJ; Bergström CAS Pharm Res; 2020 May; 37(6):99. PubMed ID: 32435855 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Digestion-In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion-Permeation Model. Tanaka Y; Arai H; Hidaka A; Noda S; Imai K; Tsujisawa F; Yagi H; Sakuma S Mol Pharm; 2024 Jul; 21(7):3459-3470. PubMed ID: 38809159 [TBL] [Abstract][Full Text] [Related]
5. Biopharmaceutical modeling of drug supersaturation during lipid-based formulation digestion considering an absorption sink. Stillhart C; Imanidis G; Griffin BT; Kuentz M Pharm Res; 2014 Dec; 31(12):3426-44. PubMed ID: 24962509 [TBL] [Abstract][Full Text] [Related]
6. Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation. Suys EJA; Chalmers DK; Pouton CW; Porter CJH Mol Pharm; 2018 Jun; 15(6):2355-2371. PubMed ID: 29659287 [TBL] [Abstract][Full Text] [Related]
7. Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation? Alskär LC; Parrow A; Keemink J; Johansson P; Abrahamsson B; Bergström CAS J Control Release; 2019 Jun; 304():90-100. PubMed ID: 31047962 [TBL] [Abstract][Full Text] [Related]
9. Interaction with biliary and pancreatic fluids drives supersaturation and drug absorption from lipid-based formulations of low (saquinavir) and high (fenofibrate) permeability poorly soluble drugs. Suys EJA; Brundel DHS; Chalmers DK; Pouton CW; Porter CJH J Control Release; 2021 Mar; 331():45-61. PubMed ID: 33450318 [TBL] [Abstract][Full Text] [Related]
10. Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623. McEvoy CL; Trevaskis NL; Feeney OM; Edwards GA; Perlman ME; Ambler CM; Porter CJH Mol Pharm; 2017 Dec; 14(12):4525-4538. PubMed ID: 29076741 [TBL] [Abstract][Full Text] [Related]
11. Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods. Crum MF; Trevaskis NL; Pouton CW; Porter CJ Mol Pharm; 2017 Feb; 14(2):394-405. PubMed ID: 28002666 [TBL] [Abstract][Full Text] [Related]
12. Caco-2 Cell Conditions Enabling Studies of Drug Absorption from Digestible Lipid-Based Formulations. Keemink J; Bergström CAS Pharm Res; 2018 Feb; 35(4):74. PubMed ID: 29484506 [TBL] [Abstract][Full Text] [Related]
13. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. Williams HD; Sassene P; Kleberg K; Calderone M; Igonin A; Jule E; Vertommen J; Blundell R; Benameur H; Müllertz A; Porter CJ; Pouton CW; J Pharm Sci; 2014 Aug; 103(8):2441-55. PubMed ID: 24985238 [TBL] [Abstract][Full Text] [Related]
14. Benefits of combining supersaturating and solubilizing formulations - Is two better than one? Alvebratt C; Karlén F; Åhlén M; Edueng K; Dubbelboer I; Bergström CAS Int J Pharm; 2024 Sep; 663():124437. PubMed ID: 39002818 [TBL] [Abstract][Full Text] [Related]
15. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. Williams HD; Anby MU; Sassene P; Kleberg K; Bakala-N'Goma JC; Calderone M; Jannin V; Igonin A; Partheil A; Marchaud D; Jule E; Vertommen J; Maio M; Blundell R; Benameur H; Carrière F; Müllertz A; Pouton CW; Porter CJ Mol Pharm; 2012 Nov; 9(11):3286-300. PubMed ID: 23030411 [TBL] [Abstract][Full Text] [Related]
16. In Situ Lipolysis and Synchrotron Small-Angle X-ray Scattering for the Direct Determination of the Precipitation and Solid-State Form of a Poorly Water-Soluble Drug During Digestion of a Lipid-Based Formulation. Khan J; Hawley A; Rades T; Boyd BJ J Pharm Sci; 2016 Sep; 105(9):2631-2639. PubMed ID: 26359590 [TBL] [Abstract][Full Text] [Related]
17. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. Feeney OM; Williams HD; Pouton CW; Porter CJ J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571 [TBL] [Abstract][Full Text] [Related]
18. Digestion of Lipid-Based Formulations Not Only Mediates Changes to Absorption of Poorly Soluble Drugs Due to Differences in Solubilization But Also Reflects Changes to Thermodynamic Activity and Permeability. Tanaka Y; Nguyen TH; Suys EJA; Porter CJH Mol Pharm; 2021 Apr; 18(4):1768-1778. PubMed ID: 33729806 [TBL] [Abstract][Full Text] [Related]
19. Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs. Carrière F Biochimie; 2016 Jun; 125():297-305. PubMed ID: 26607242 [TBL] [Abstract][Full Text] [Related]
20. Enabling superior drug loading in lipid-based formulations with lipophilic salts for a brick dust molecule: Exploration of lipophilic counterions and in vitro-in vivo evaluation. Sirvi A; Jadhav K; Sangamwar AT Int J Pharm; 2024 May; 656():124108. PubMed ID: 38604540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]